Skip to main content

Table 2 Adjusted HbA1c reduction over 12 month period in patients switching from premix to glargine*

From: Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary care-based analysis

Variable

Type 1 (n = 183)

Type 2 (n = 345)

No.

Δ HbA 1c (%)

p-value†

No.

Δ HbA 1c (%)

p-value†

Overall

183

-0.67

<0.001

345

-0.53

<0.001

By baseline HbA1c level

   ≥ 7%

151

-0.67

<0.001

306

-0.56

<0.001

   ≥ 8%

128

-0.80

<0.001

255

-0.68

<0.001

   ≥ 9%

86

-1.06

<0.001

169

-0.84

<0.001

   ≥ 10%

46

-1.74

<0.001

88

-1.20

<0.001

  1. OAD = oral antidiabetic drugs; HbA1c = glycated haemoglobin.
  2. *Adjusted for demographic and clinical covariates including age, weight, hypoglycaemia, concomitant use of OADs and baseline HbA1c (in the 3 months prior to insulin initiation).
  3. †p-values by the paired t-test for difference in mean HbA1c following switch from premix to glargine.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840